1. Frangoul, Haydar, Altshuler, David, Cappellini, M Domenica, Yen, Angela, Corbacioglu, Selim. 2020. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. In The New England journal of medicine, 384, 252-260. doi:10.1056/NEJMoa2031054. https://pubmed.ncbi.nlm.nih.gov/33283989/
2. Fu, Bin, Liao, Jiaoyang, Chen, Shuanghong, Liu, Mingyao, Wu, Yuxuan. 2022. CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric β0/β0 transfusion-dependent β-thalassemia. In Nature medicine, 28, 1573-1580. doi:10.1038/s41591-022-01906-z. https://pubmed.ncbi.nlm.nih.gov/35922667/
3. Mahmoud Ahmed, Nahil Hassan, Lai, Mei I. . The Novel Role of the B-Cell Lymphoma/Leukemia 11A (BCL11A) Gene in β-Thalassaemia Treatment. In Cardiovascular & hematological disorders drug targets, 22, 226-236. doi:10.2174/1871529X23666230123140926. https://pubmed.ncbi.nlm.nih.gov/36734897/
4. Liu, Nan, Hargreaves, Victoria V, Zhu, Qian, Bulyk, Martha L, Orkin, Stuart H. 2018. Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch. In Cell, 173, 430-442.e17. doi:10.1016/j.cell.2018.03.016. https://pubmed.ncbi.nlm.nih.gov/29606353/
5. Demirci, Selami, Uchida, Naoya, Tisdale, John F. 2018. Gene therapy for sickle cell disease: An update. In Cytotherapy, 20, 899-910. doi:10.1016/j.jcyt.2018.04.003. https://pubmed.ncbi.nlm.nih.gov/29859773/
6. Esrick, Erica B, Lehmann, Leslie E, Biffi, Alessandra, Manis, John P, Williams, David A. 2020. Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. In The New England journal of medicine, 384, 205-215. doi:10.1056/NEJMoa2029392. https://pubmed.ncbi.nlm.nih.gov/33283990/
智鼠故事 
